Cabaletta Bio Inc Ordinary Shares CABA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cabaletta Bio to Participate in Upcoming Investor Conferences
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cabaletta Bio to Participate in Upcoming Investor Conferences
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Cabaletta Bio Shares Rise on Autoimmune-Disease Trial Results
Trading Information
- Previous Close Price
- $1.50
- Day Range
- $1.41–1.54
- 52-Week Range
- $1.18–4.23
- Bid/Ask
- $1.46 / $1.48
- Shares Outstanding
- 215.72M
- Market Cap
- $312.79M
- Volume/Avg
- 4M / 5M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 158
- Website
- https://www.cabalettabio.com
Valuation
Metric | CABA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.10 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | CABA |
|---|---|
Quick Ratio | 6.33 |
Current Ratio | 6.55 |
Interest Coverage | −87.17 |
Quick Ratio
CABA
Profitability
Metric | CABA |
|---|---|
Return on Assets (Normalized) | −77.12% |
Return on Equity (Normalized) | −99.53% |
Return on Invested Capital (Normalized) | −88.49% |
Return on Assets
CABA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|?S@dH$C | LOCK|JRqVr | $139B | |||
| Moderna Inc MRNA | LOCK|<!MY!t | LOCK|s?@ | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|<#pGRCY | LOCK|b@yv | $95B | |||
| argenx SE ADR ARGX | LOCK|&!hqq> | LOCK|!y^ | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|$@<J$# | LOCK|BR | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|x<sFp%?# | LOCK|!>GN$ | $31B | |||
| Incyte Corp INCY | LOCK|^&%qSZ | LOCK|#PW | $25B | |||
| BioNTech SE ADR BNTX | LOCK|!DzLknT | LOCK|xC | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|?!&S#S | LOCK|<Bw#P | $20B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|<PjPs<p | LOCK|Gsc | $16B |
United States